The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells.
Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells. Asplatin is highly accumulated in cancer cells and is activated upon the reduction by ascorbic acid.
CAS Key Laboratory of Soft Matter Chemistry, CAS High Magnetic Field Laboratory, Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, China. liuyz@ustc.edu.cn.
Qinqin
Q
Cheng
Hongdong
H
Shi
Hongxia
H
Wang
Yuanzeng
Y
Min
Jun
J
Wang
Yangzhong
Y
Liu
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000737:chemistry*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry*; D001241:Aspirin / Q000008:administration & dosage / Q000737:chemistry*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000737:chemistry*; D004338:Drug Combinations; D004357:Drug Synergism; D056945:Hep G2 Cells; D006801:Humans; D061986:MCF-7 Cells; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D047368:Tumor Burden / Q000187:drug effects*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D004338:Drug Combinations; D002945:Cisplatin; D001241:Aspirin